Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:GRDX NASDAQ:NLTX NASDAQ:NXTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.22-1.6%$1.34$1.01▼$8.08$33.57M0.31932,054 shs563,694 shsGRDXEntero Therapeutics$3.42+20.0%$2.30$1.06▼$5.84$9.58M1.38108,705 shs258,236 shsNLTXNeoleukin Therapeutics$31.26-3.3%$22.79$2.03▼$14.36$293.78M1.1150,104 shs152,690 shsNXTCNextCure$9.76-4.1%$11.31$4.60▼$15.74$36.72M1.4373,533 shs9,494 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-4.62%+0.81%+13.76%-17.33%-18.95%GRDXEntero Therapeutics+11.33%+13.55%+31.94%-2.06%+284,999,900.00%NLTXNeoleukin Therapeutics0.00%+7.07%+41.38%+76.79%+121.76%NXTCNextCure-5.04%+10.53%-8.54%-8.29%+123.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.22-1.6%$1.34$1.01▼$8.08$33.57M0.31932,054 shs563,694 shsGRDXEntero Therapeutics$3.42+20.0%$2.30$1.06▼$5.84$9.58M1.38108,705 shs258,236 shsNLTXNeoleukin Therapeutics$31.26-3.3%$22.79$2.03▼$14.36$293.78M1.1150,104 shs152,690 shsNXTCNextCure$9.76-4.1%$11.31$4.60▼$15.74$36.72M1.4373,533 shs9,494 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics-4.62%+0.81%+13.76%-17.33%-18.95%GRDXEntero Therapeutics+11.33%+13.55%+31.94%-2.06%+284,999,900.00%NLTXNeoleukin Therapeutics0.00%+7.07%+41.38%+76.79%+121.76%NXTCNextCure-5.04%+10.53%-8.54%-8.29%+123.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.25Hold$11.00801.64% UpsideGRDXEntero Therapeutics 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/ANXTCNextCure 2.20Hold$23.00135.66% UpsideCurrent Analyst Ratings BreakdownLatest GRDX, NXTC, NLTX, and BTAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026NXTCNextCure Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/27/2026NXTCNextCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BTAIBioXcel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/2/2026BTAIBioXcel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$6.00 ➝ $5.003/17/2026BTAIBioXcel Therapeutics Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$17.003/9/2026BTAIBioXcel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/5/2026BTAIBioXcel Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $6.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$642K51.45N/AN/A($4.37) per share-0.28GRDXEntero Therapeutics$40K287.28N/AN/A($2.45) per share-1.40NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ANXTCNextCureN/AN/AN/AN/A$9.97 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$69.90M-$6.71N/AN/AN/A-10,887.38%N/A-181.48%5/11/2026 (Estimated)GRDXEntero Therapeutics-$18.06M-$1.69N/AN/AN/AN/A-461.02%-14.72%N/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/AN/AN/AN/A-37.22%-30.91%N/ANXTCNextCure-$55.84M-$17.19N/AN/AN/AN/A-152.90%-109.17%N/ALatest GRDX, NXTC, NLTX, and BTAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026BTAIBioXcel Therapeutics-$0.5325N/AN/AN/A$0.39 millionN/A5/7/2026Q1 2026NXTCNextCure-$2.1050-$1.87+$0.2350-$1.87N/AN/A5/1/2026Q4 2025GRDXEntero TherapeuticsN/A-$1.88N/A-$1.88N/AN/A3/27/2026Q4 2025BTAIBioXcel Therapeutics-$0.58-$0.58N/A$0.65$0.15 millionN/A3/5/2026Q4 2025NXTCNextCure-$2.26-$0.81+$1.45-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AGRDXEntero TherapeuticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A0.830.82GRDXEntero TherapeuticsN/A2.622.62NLTXNeoleukin TherapeuticsN/A15.3315.33NXTCNextCureN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%GRDXEntero Therapeutics12.30%NLTXNeoleukin Therapeutics52.37%NXTCNextCure42.65%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics3.70%GRDXEntero Therapeutics0.75%NLTXNeoleukin Therapeutics1.58%NXTCNextCure11.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics9027.08 million26.07 millionNo DataGRDXEntero Therapeutics93.36 million3.34 millionN/ANLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataNXTCNextCure903.61 million3.18 millionNo DataGRDX, NXTC, NLTX, and BTAI HeadlinesRecent News About These CompaniesNextCure Provides Business Update and Reports First Quarter 2026 Financial ResultsMay 7 at 4:05 PM | globenewswire.comNextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic CancersMay 4, 2026 | globenewswire.comNextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026April 21, 2026 | markets.businessinsider.comNextCure and Simcere Announce Presentation of Phase 1 Data for SIM0505 at ASCO 2026April 21, 2026 | quiverquant.comQNextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026April 21, 2026 | globenewswire.comNextCure Insider Trading Activity | NASDAQ:NXTC | BenzingaApril 10, 2026 | benzinga.comNextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian CancerApril 7, 2026 | globenewswire.comNextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026March 31, 2026 | markets.businessinsider.comNextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026March 31, 2026 | globenewswire.comNextCure Provides Business Update and Reports Full Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comNextCure Provides Business UpdateJanuary 23, 2026 | globenewswire.comNextCure launches at-the-market stock offering programDecember 20, 2025 | msn.comNextCure files to sell 2.52M shares of common stock for holdersNovember 26, 2025 | msn.comNextCure to Present at the Piper Sandler 37th Annual Healthcare ConferenceNovember 20, 2025 | globenewswire.comNextCure announces closing of $21.5M PIPE financingNovember 18, 2025 | msn.comNextCure Raises $21.5M in Private PlacementNovember 17, 2025 | tipranks.comNextCure, Inc. Secures $21.5 Million in Private Placement, Extending Cash Runway into First Half of 2027November 17, 2025 | quiverquant.comQNextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data ReadoutsNovember 17, 2025 | globenewswire.comNextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq RulesNovember 12, 2025 | globenewswire.comDoes NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?November 11, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRDX, NXTC, NLTX, and BTAI Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$1.22 -0.02 (-1.61%) Closing price 04:00 PM EasternExtended Trading$1.22 0.00 (-0.33%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Entero Therapeutics NASDAQ:GRDX$3.42 +0.57 (+20.00%) Closing price 04:00 PM EasternExtended Trading$3.61 +0.19 (+5.56%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Neoleukin Therapeutics NASDAQ:NLTX$31.26 -1.07 (-3.31%) As of 05/7/2026Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.NextCure NASDAQ:NXTC$9.76 -0.42 (-4.13%) Closing price 04:00 PM EasternExtended Trading$9.88 +0.13 (+1.28%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
